Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Stem Neoplasms | 33 | 2023 | 192 | 8.250 |
Why?
|
Glioma | 39 | 2024 | 3493 | 3.340 |
Why?
|
Pons | 10 | 2017 | 239 | 2.600 |
Why?
|
Central Nervous System Neoplasms | 10 | 2022 | 917 | 2.130 |
Why?
|
Endpoint Determination | 3 | 2020 | 591 | 1.680 |
Why?
|
Macaca mulatta | 16 | 2020 | 2341 | 1.610 |
Why?
|
Brain Neoplasms | 26 | 2024 | 9071 | 1.390 |
Why?
|
Antineoplastic Agents | 17 | 2023 | 13639 | 1.170 |
Why?
|
Medulloblastoma | 5 | 2022 | 657 | 1.080 |
Why?
|
Cerebrospinal Fluid | 2 | 2020 | 538 | 0.960 |
Why?
|
Dacarbazine | 6 | 2017 | 552 | 0.930 |
Why?
|
Blood-Brain Barrier | 6 | 2020 | 1036 | 0.920 |
Why?
|
Astrocytoma | 3 | 2023 | 772 | 0.890 |
Why?
|
Posterior Leukoencephalopathy Syndrome | 1 | 2023 | 49 | 0.840 |
Why?
|
Magnetic Resonance Spectroscopy | 6 | 2018 | 3673 | 0.770 |
Why?
|
Angiogenesis Inhibitors | 3 | 2020 | 2046 | 0.750 |
Why?
|
Models, Animal | 4 | 2016 | 2120 | 0.730 |
Why?
|
Thalidomide | 2 | 2020 | 886 | 0.730 |
Why?
|
Inulin | 1 | 2020 | 67 | 0.710 |
Why?
|
Cerebellar Neoplasms | 4 | 2022 | 571 | 0.710 |
Why?
|
Child | 67 | 2024 | 80499 | 0.680 |
Why?
|
Receptor, Macrophage Colony-Stimulating Factor | 1 | 2020 | 94 | 0.680 |
Why?
|
Neutropenia | 2 | 2023 | 893 | 0.640 |
Why?
|
Public Health Practice | 2 | 2018 | 219 | 0.610 |
Why?
|
Baltimore | 6 | 2018 | 232 | 0.600 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2018 | 330 | 0.600 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2018 | 43 | 0.600 |
Why?
|
Phosphorylcholine | 2 | 2017 | 151 | 0.590 |
Why?
|
Magnetic Resonance Imaging | 25 | 2023 | 36537 | 0.570 |
Why?
|
Designer Drugs | 1 | 2017 | 21 | 0.560 |
Why?
|
Child, Preschool | 42 | 2024 | 42468 | 0.550 |
Why?
|
Interinstitutional Relations | 1 | 2018 | 234 | 0.550 |
Why?
|
Bradykinin | 5 | 2006 | 205 | 0.540 |
Why?
|
Thrombocytopenia | 2 | 2023 | 1171 | 0.530 |
Why?
|
Aminopyridines | 1 | 2020 | 576 | 0.520 |
Why?
|
Carboplatin | 6 | 2011 | 789 | 0.500 |
Why?
|
Pyrroles | 3 | 2022 | 1119 | 0.500 |
Why?
|
Measles | 1 | 2017 | 180 | 0.490 |
Why?
|
Choline | 3 | 2012 | 511 | 0.470 |
Why?
|
Cannabinoids | 1 | 2017 | 174 | 0.470 |
Why?
|
Aspartic Acid | 3 | 2012 | 576 | 0.460 |
Why?
|
Alcoholic Beverages | 1 | 2016 | 265 | 0.450 |
Why?
|
Catheters, Indwelling | 2 | 2016 | 438 | 0.440 |
Why?
|
Tumor Burden | 5 | 2022 | 1884 | 0.430 |
Why?
|
Neoplasms, Nerve Tissue | 1 | 2013 | 20 | 0.430 |
Why?
|
Alcohol-Related Disorders | 1 | 2016 | 242 | 0.430 |
Why?
|
Microdialysis | 1 | 2013 | 156 | 0.420 |
Why?
|
Guanine | 3 | 2011 | 282 | 0.420 |
Why?
|
Catheterization | 2 | 2016 | 1427 | 0.410 |
Why?
|
Adolescent | 43 | 2024 | 88781 | 0.400 |
Why?
|
Brain Stem | 4 | 2017 | 854 | 0.390 |
Why?
|
Meningeal Neoplasms | 2 | 2018 | 1253 | 0.380 |
Why?
|
Pharmaceutical Preparations | 1 | 2019 | 1084 | 0.370 |
Why?
|
Area Under Curve | 7 | 2018 | 1639 | 0.360 |
Why?
|
Comparative Genomic Hybridization | 1 | 2011 | 474 | 0.340 |
Why?
|
Specimen Handling | 1 | 2015 | 703 | 0.340 |
Why?
|
Bayes Theorem | 1 | 2018 | 2354 | 0.340 |
Why?
|
Protons | 3 | 2011 | 1073 | 0.330 |
Why?
|
Hydroxamic Acids | 2 | 2015 | 483 | 0.330 |
Why?
|
Ethanol | 1 | 2016 | 1324 | 0.330 |
Why?
|
Maximum Tolerated Dose | 5 | 2020 | 898 | 0.320 |
Why?
|
Age of Onset | 3 | 2020 | 3339 | 0.310 |
Why?
|
Ependymoma | 3 | 2022 | 310 | 0.310 |
Why?
|
Humans | 95 | 2024 | 765734 | 0.310 |
Why?
|
Male | 57 | 2024 | 363585 | 0.310 |
Why?
|
Standard of Care | 1 | 2013 | 567 | 0.300 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2009 | 135 | 0.300 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2020 | 2805 | 0.300 |
Why?
|
Supratentorial Neoplasms | 1 | 2009 | 153 | 0.300 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2020 | 10730 | 0.290 |
Why?
|
Interferon-alpha | 1 | 2011 | 910 | 0.280 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2023 | 11865 | 0.280 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2017 | 2454 | 0.280 |
Why?
|
Tissue Distribution | 3 | 2020 | 2266 | 0.260 |
Why?
|
Consensus | 4 | 2020 | 3200 | 0.260 |
Why?
|
Metabolic Clearance Rate | 3 | 2018 | 361 | 0.260 |
Why?
|
Polyethylene Glycols | 1 | 2011 | 1188 | 0.250 |
Why?
|
Administration, Intranasal | 2 | 2018 | 482 | 0.250 |
Why?
|
Public Health | 2 | 2016 | 2678 | 0.250 |
Why?
|
Molecular Imaging | 1 | 2012 | 822 | 0.240 |
Why?
|
Chromosome Aberrations | 1 | 2011 | 1774 | 0.240 |
Why?
|
Infusions, Intravenous | 7 | 2015 | 2229 | 0.240 |
Why?
|
Health Promotion | 1 | 2017 | 2208 | 0.240 |
Why?
|
Animals | 27 | 2023 | 168731 | 0.240 |
Why?
|
Half-Life | 4 | 2018 | 645 | 0.230 |
Why?
|
Neoplasms | 8 | 2019 | 22345 | 0.230 |
Why?
|
Positron-Emission Tomography | 5 | 2022 | 6546 | 0.230 |
Why?
|
Time Factors | 10 | 2020 | 40066 | 0.220 |
Why?
|
Radiation Tolerance | 2 | 2017 | 475 | 0.220 |
Why?
|
Neurotoxicity Syndromes | 1 | 2008 | 302 | 0.220 |
Why?
|
Diffusion Tensor Imaging | 1 | 2014 | 2415 | 0.220 |
Why?
|
Osteosarcoma | 1 | 2009 | 909 | 0.210 |
Why?
|
Opioid-Related Disorders | 1 | 2018 | 2178 | 0.210 |
Why?
|
Doxorubicin | 2 | 2000 | 2229 | 0.210 |
Why?
|
Predictive Value of Tests | 5 | 2020 | 15390 | 0.210 |
Why?
|
Infant | 17 | 2018 | 36363 | 0.210 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2022 | 2024 | 0.200 |
Why?
|
Drug Administration Schedule | 6 | 2013 | 4850 | 0.200 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2007 | 778 | 0.200 |
Why?
|
Research Design | 1 | 2018 | 6207 | 0.200 |
Why?
|
Protein Kinase Inhibitors | 2 | 2017 | 5693 | 0.200 |
Why?
|
Organoplatinum Compounds | 2 | 2015 | 404 | 0.190 |
Why?
|
Neoplasms, Second Primary | 1 | 2009 | 1048 | 0.190 |
Why?
|
Prognosis | 10 | 2024 | 29899 | 0.180 |
Why?
|
Gangliosides | 1 | 2022 | 132 | 0.180 |
Why?
|
Female | 41 | 2024 | 395961 | 0.180 |
Why?
|
Exotoxins | 2 | 2018 | 123 | 0.180 |
Why?
|
Stroke | 1 | 2023 | 9747 | 0.180 |
Why?
|
Intracranial Pressure | 1 | 2023 | 323 | 0.180 |
Why?
|
Young Adult | 18 | 2024 | 59852 | 0.180 |
Why?
|
Substance-Related Disorders | 1 | 2017 | 4417 | 0.170 |
Why?
|
Clinical Trials as Topic | 2 | 2013 | 8038 | 0.170 |
Why?
|
Brain | 5 | 2023 | 27178 | 0.170 |
Why?
|
Craniopharyngioma | 1 | 2023 | 276 | 0.170 |
Why?
|
Immunotherapy, Adoptive | 2 | 2022 | 1511 | 0.170 |
Why?
|
Rhabdoid Tumor | 1 | 2022 | 209 | 0.170 |
Why?
|
Nasal Mucosa | 1 | 2023 | 416 | 0.170 |
Why?
|
Fluconazole | 1 | 2000 | 154 | 0.160 |
Why?
|
Biological Availability | 1 | 2020 | 386 | 0.160 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2017 | 347 | 0.160 |
Why?
|
Survival Rate | 6 | 2024 | 12787 | 0.160 |
Why?
|
Interleukin-13 | 2 | 2018 | 388 | 0.160 |
Why?
|
Histones | 2 | 2022 | 2592 | 0.160 |
Why?
|
Infusions, Intraventricular | 1 | 2018 | 31 | 0.150 |
Why?
|
Perfusion Imaging | 1 | 2020 | 193 | 0.150 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2024 | 954 | 0.150 |
Why?
|
Carcinoma, Medullary | 1 | 1999 | 114 | 0.150 |
Why?
|
Sickle Cell Trait | 1 | 1999 | 86 | 0.150 |
Why?
|
Creatine | 2 | 2012 | 424 | 0.150 |
Why?
|
Smith-Lemli-Opitz Syndrome | 1 | 2017 | 46 | 0.150 |
Why?
|
Local Government | 1 | 2018 | 83 | 0.140 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 480 | 0.140 |
Why?
|
Neoplasm Seeding | 1 | 2018 | 85 | 0.140 |
Why?
|
Hematuria | 1 | 1999 | 230 | 0.140 |
Why?
|
Neurofibromatosis 1 | 2 | 2017 | 560 | 0.140 |
Why?
|
Organizational Case Studies | 1 | 2018 | 300 | 0.140 |
Why?
|
Adrenal Cortex Hormones | 2 | 2018 | 1880 | 0.140 |
Why?
|
Drug Labeling | 1 | 2019 | 251 | 0.140 |
Why?
|
Measles Vaccine | 1 | 2017 | 79 | 0.140 |
Why?
|
Cerebral Cortex | 1 | 2013 | 5768 | 0.140 |
Why?
|
Cyclosporine | 1 | 2000 | 777 | 0.140 |
Why?
|
Bone Neoplasms | 1 | 2009 | 2564 | 0.140 |
Why?
|
Enzyme Inhibitors | 1 | 2007 | 3717 | 0.140 |
Why?
|
Administration, Oral | 3 | 2015 | 4015 | 0.140 |
Why?
|
Immunomodulation | 1 | 2020 | 547 | 0.130 |
Why?
|
Kaplan-Meier Estimate | 4 | 2018 | 6499 | 0.130 |
Why?
|
Registries | 5 | 2022 | 8293 | 0.130 |
Why?
|
Treatment Outcome | 10 | 2023 | 65180 | 0.130 |
Why?
|
Benzoxazoles | 1 | 2017 | 91 | 0.130 |
Why?
|
Civil Disorders | 1 | 2015 | 8 | 0.130 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2000 | 679 | 0.130 |
Why?
|
Powders | 1 | 2016 | 78 | 0.130 |
Why?
|
Public Health Administration | 1 | 2018 | 242 | 0.130 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2019 | 1332 | 0.120 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2022 | 949 | 0.120 |
Why?
|
Social Problems | 1 | 2015 | 107 | 0.120 |
Why?
|
Antifungal Agents | 1 | 2000 | 769 | 0.120 |
Why?
|
Pathology, Molecular | 1 | 2018 | 329 | 0.120 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2018 | 791 | 0.120 |
Why?
|
Pituitary Neoplasms | 1 | 2023 | 1322 | 0.110 |
Why?
|
Valproic Acid | 1 | 2017 | 444 | 0.110 |
Why?
|
Autopsy | 2 | 2016 | 1011 | 0.110 |
Why?
|
Civil Defense | 1 | 2015 | 114 | 0.110 |
Why?
|
Injections, Intravenous | 3 | 2013 | 1377 | 0.110 |
Why?
|
Drug Monitoring | 1 | 2020 | 961 | 0.110 |
Why?
|
High-Throughput Screening Assays | 1 | 2019 | 938 | 0.110 |
Why?
|
Lateral Ventricles | 1 | 2015 | 142 | 0.110 |
Why?
|
Pyrimidines | 2 | 2017 | 3044 | 0.110 |
Why?
|
Brain Edema | 1 | 2018 | 602 | 0.110 |
Why?
|
5-Methylcytosine | 1 | 2014 | 146 | 0.110 |
Why?
|
Mutation | 4 | 2024 | 30184 | 0.110 |
Why?
|
SEER Program | 1 | 2018 | 1444 | 0.110 |
Why?
|
Police | 1 | 2015 | 158 | 0.110 |
Why?
|
Vincristine | 1 | 2015 | 1038 | 0.110 |
Why?
|
Cytosine | 1 | 2014 | 212 | 0.100 |
Why?
|
Benzazepines | 1 | 2015 | 308 | 0.100 |
Why?
|
State Government | 1 | 2016 | 388 | 0.100 |
Why?
|
Adult | 21 | 2024 | 222974 | 0.100 |
Why?
|
Recombinant Fusion Proteins | 2 | 2018 | 3737 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2022 | 2056 | 0.100 |
Why?
|
DNA, Neoplasm | 2 | 2022 | 1740 | 0.100 |
Why?
|
Poultry Diseases | 1 | 2012 | 24 | 0.100 |
Why?
|
Community Health Services | 1 | 2017 | 657 | 0.100 |
Why?
|
Salmonella Infections, Animal | 1 | 2012 | 60 | 0.100 |
Why?
|
Fourth Ventricle | 1 | 2012 | 32 | 0.100 |
Why?
|
Indoles | 2 | 2022 | 1832 | 0.100 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2015 | 616 | 0.100 |
Why?
|
Clinical Protocols | 1 | 2017 | 1441 | 0.090 |
Why?
|
Prospective Studies | 7 | 2022 | 54795 | 0.090 |
Why?
|
Cholesterol | 2 | 2017 | 2898 | 0.090 |
Why?
|
Attitude to Death | 1 | 2014 | 400 | 0.090 |
Why?
|
United States Food and Drug Administration | 1 | 2019 | 1672 | 0.090 |
Why?
|
Drug Carriers | 1 | 2015 | 700 | 0.090 |
Why?
|
Zoonoses | 1 | 2012 | 180 | 0.090 |
Why?
|
Basilar Artery | 1 | 2012 | 206 | 0.090 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 2423 | 0.090 |
Why?
|
DNA Modification Methylases | 1 | 2011 | 207 | 0.090 |
Why?
|
Health Education | 1 | 2017 | 1060 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2016 | 8603 | 0.090 |
Why?
|
Paraffin Embedding | 1 | 2011 | 301 | 0.090 |
Why?
|
Salmonella Infections | 1 | 2012 | 176 | 0.090 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 614 | 0.090 |
Why?
|
Drug Prescriptions | 1 | 2019 | 1663 | 0.090 |
Why?
|
International Cooperation | 1 | 2017 | 1432 | 0.090 |
Why?
|
Bereavement | 1 | 2014 | 309 | 0.090 |
Why?
|
Disease Outbreaks | 2 | 2017 | 1760 | 0.090 |
Why?
|
Statistics, Nonparametric | 2 | 2014 | 2845 | 0.080 |
Why?
|
Camptothecin | 1 | 2013 | 600 | 0.080 |
Why?
|
Follow-Up Studies | 4 | 2024 | 39180 | 0.080 |
Why?
|
Neurology | 1 | 2018 | 784 | 0.080 |
Why?
|
DNA Repair Enzymes | 1 | 2011 | 342 | 0.080 |
Why?
|
Organs at Risk | 1 | 2012 | 352 | 0.080 |
Why?
|
Pilot Projects | 2 | 2019 | 8732 | 0.080 |
Why?
|
Disaster Planning | 1 | 2015 | 559 | 0.080 |
Why?
|
Ki-67 Antigen | 1 | 2011 | 627 | 0.080 |
Why?
|
Age Factors | 6 | 2024 | 18375 | 0.080 |
Why?
|
Infant, Newborn | 7 | 2022 | 26332 | 0.080 |
Why?
|
United States | 7 | 2019 | 72898 | 0.080 |
Why?
|
Benzimidazoles | 1 | 2014 | 864 | 0.080 |
Why?
|
Longitudinal Studies | 3 | 2022 | 14745 | 0.080 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2019 | 3605 | 0.080 |
Why?
|
Epigenomics | 1 | 2014 | 959 | 0.080 |
Why?
|
Radiopharmaceuticals | 2 | 2022 | 2699 | 0.070 |
Why?
|
Constriction, Pathologic | 1 | 2012 | 1105 | 0.070 |
Why?
|
Imaging, Three-Dimensional | 1 | 2001 | 4036 | 0.070 |
Why?
|
Proportional Hazards Models | 2 | 2013 | 12509 | 0.070 |
Why?
|
Informed Consent | 1 | 2014 | 1010 | 0.070 |
Why?
|
Receptor, erbB-2 | 1 | 2018 | 2592 | 0.070 |
Why?
|
Drug Therapy, Combination | 2 | 2011 | 6307 | 0.070 |
Why?
|
Disease-Free Survival | 2 | 2011 | 6832 | 0.070 |
Why?
|
Population Surveillance | 1 | 2017 | 2589 | 0.070 |
Why?
|
Gaucher Disease | 1 | 2007 | 110 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2013 | 9368 | 0.070 |
Why?
|
Lumbar Vertebrae | 1 | 2016 | 1874 | 0.070 |
Why?
|
Maternal Behavior | 1 | 2008 | 306 | 0.060 |
Why?
|
Combined Modality Therapy | 4 | 2011 | 8528 | 0.060 |
Why?
|
Health Policy | 1 | 2018 | 2699 | 0.060 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2822 | 0.060 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2008 | 639 | 0.060 |
Why?
|
Hydrocephalus | 1 | 2012 | 767 | 0.060 |
Why?
|
Hematologic Diseases | 1 | 2009 | 500 | 0.060 |
Why?
|
Epigenesis, Genetic | 1 | 2018 | 3818 | 0.060 |
Why?
|
Immunohistochemistry | 2 | 2013 | 11007 | 0.060 |
Why?
|
Computer Simulation | 1 | 2018 | 6252 | 0.060 |
Why?
|
Mice, Inbred C57BL | 1 | 2023 | 22321 | 0.060 |
Why?
|
Mother-Child Relations | 1 | 2008 | 499 | 0.060 |
Why?
|
Neurofibroma, Plexiform | 1 | 2004 | 66 | 0.060 |
Why?
|
Models, Statistical | 1 | 2018 | 5088 | 0.050 |
Why?
|
Drug Synergism | 2 | 2019 | 1749 | 0.050 |
Why?
|
Biopsy | 2 | 2013 | 6754 | 0.050 |
Why?
|
Disease Models, Animal | 3 | 2018 | 18289 | 0.050 |
Why?
|
Quality of Life | 4 | 2023 | 13462 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2012 | 5302 | 0.050 |
Why?
|
Contrast Media | 2 | 2014 | 5326 | 0.050 |
Why?
|
Mice | 4 | 2023 | 81792 | 0.050 |
Why?
|
Disease Progression | 3 | 2018 | 13614 | 0.050 |
Why?
|
Perfusion | 1 | 2007 | 1407 | 0.050 |
Why?
|
Drug Delivery Systems | 1 | 2013 | 2207 | 0.050 |
Why?
|
Tissue Array Analysis | 2 | 2014 | 544 | 0.050 |
Why?
|
Kidney Neoplasms | 1 | 1999 | 4262 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2022 | 8926 | 0.050 |
Why?
|
Observer Variation | 1 | 2008 | 2611 | 0.050 |
Why?
|
Recombinant Proteins | 1 | 2011 | 6492 | 0.050 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 2009 | 1526 | 0.050 |
Why?
|
Man-Machine Systems | 1 | 2001 | 42 | 0.050 |
Why?
|
Flushing | 1 | 2001 | 52 | 0.050 |
Why?
|
Primary Health Care | 1 | 2018 | 4737 | 0.050 |
Why?
|
Tumor Suppressor Proteins | 1 | 2011 | 2794 | 0.050 |
Why?
|
Pyrimidine Nucleosides | 1 | 2000 | 6 | 0.050 |
Why?
|
Schizophrenic Psychology | 1 | 2008 | 1650 | 0.050 |
Why?
|
Drug Interactions | 2 | 2009 | 1416 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2024 | 81457 | 0.040 |
Why?
|
Adaptation, Psychological | 1 | 2011 | 2660 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5506 | 0.040 |
Why?
|
Family | 1 | 2011 | 3207 | 0.040 |
Why?
|
Parents | 1 | 2014 | 3592 | 0.040 |
Why?
|
Cerebral Hemorrhage | 1 | 2012 | 2649 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7424 | 0.040 |
Why?
|
Spinal Cord Neoplasms | 1 | 2022 | 258 | 0.040 |
Why?
|
Sequence Analysis, RNA | 2 | 2019 | 2036 | 0.040 |
Why?
|
Surgery, Computer-Assisted | 1 | 2007 | 993 | 0.040 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2012 | 3359 | 0.040 |
Why?
|
Infusions, Intralesional | 1 | 2018 | 3 | 0.040 |
Why?
|
Caregivers | 1 | 2011 | 2307 | 0.040 |
Why?
|
Algorithms | 2 | 2018 | 14061 | 0.040 |
Why?
|
Reproducibility of Results | 3 | 2019 | 20120 | 0.040 |
Why?
|
Alkaloids | 1 | 2000 | 191 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7875 | 0.040 |
Why?
|
Pseudomonas | 1 | 2018 | 124 | 0.040 |
Why?
|
Recurrence | 1 | 2010 | 8498 | 0.040 |
Why?
|
Injections, Intraventricular | 1 | 2018 | 227 | 0.040 |
Why?
|
Sulfonamides | 1 | 2007 | 1981 | 0.040 |
Why?
|
Spectrometry, Fluorescence | 1 | 2000 | 697 | 0.040 |
Why?
|
Gadolinium DTPA | 2 | 2014 | 822 | 0.040 |
Why?
|
Cell Line, Tumor | 3 | 2019 | 17062 | 0.040 |
Why?
|
Lactones | 1 | 2019 | 316 | 0.030 |
Why?
|
Retreatment | 1 | 2018 | 597 | 0.030 |
Why?
|
Choroid Plexus | 1 | 2000 | 250 | 0.030 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2018 | 193 | 0.030 |
Why?
|
Ribosomal Protein S6 Kinases | 1 | 2017 | 203 | 0.030 |
Why?
|
Seizures | 2 | 2017 | 2999 | 0.030 |
Why?
|
Risk Assessment | 1 | 2018 | 24279 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14637 | 0.030 |
Why?
|
Monomeric GTP-Binding Proteins | 1 | 2017 | 197 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2013 | 10385 | 0.030 |
Why?
|
New Zealand | 1 | 2017 | 359 | 0.030 |
Why?
|
Amino Acids | 1 | 2022 | 1709 | 0.030 |
Why?
|
Class Ia Phosphatidylinositol 3-Kinase | 1 | 2016 | 76 | 0.030 |
Why?
|
Activin Receptors, Type I | 1 | 2016 | 133 | 0.030 |
Why?
|
Sphingomyelins | 1 | 2015 | 102 | 0.030 |
Why?
|
Hypotension | 1 | 2001 | 885 | 0.030 |
Why?
|
Glomerular Filtration Rate | 1 | 2004 | 2233 | 0.030 |
Why?
|
Protein Kinase C | 1 | 2000 | 1202 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 2008 | 7123 | 0.030 |
Why?
|
Basal Ganglia | 1 | 2017 | 549 | 0.030 |
Why?
|
Cerebrum | 1 | 2016 | 132 | 0.030 |
Why?
|
Neoplasm Staging | 3 | 2018 | 11201 | 0.030 |
Why?
|
Phosphoprotein Phosphatases | 1 | 2016 | 327 | 0.030 |
Why?
|
Cell Death | 1 | 2019 | 1678 | 0.030 |
Why?
|
Convection | 1 | 2014 | 30 | 0.030 |
Why?
|
Fatal Outcome | 1 | 1999 | 1831 | 0.030 |
Why?
|
Blood Vessels | 1 | 2000 | 1112 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2018 | 616 | 0.030 |
Why?
|
Stereotaxic Techniques | 1 | 2016 | 551 | 0.030 |
Why?
|
Headache | 1 | 2001 | 1260 | 0.030 |
Why?
|
Mitotic Index | 1 | 2013 | 158 | 0.030 |
Why?
|
Lymphoma, B-Cell | 1 | 2000 | 943 | 0.030 |
Why?
|
Australia | 1 | 2017 | 1258 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2017 | 1837 | 0.030 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2014 | 429 | 0.020 |
Why?
|
Poultry | 1 | 2012 | 79 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2015 | 967 | 0.020 |
Why?
|
Mice, SCID | 1 | 2017 | 2627 | 0.020 |
Why?
|
Liposomes | 1 | 2015 | 787 | 0.020 |
Why?
|
Salmonella | 1 | 2012 | 122 | 0.020 |
Why?
|
Serotyping | 1 | 2012 | 330 | 0.020 |
Why?
|
Canada | 1 | 2017 | 2119 | 0.020 |
Why?
|
Oncogene Proteins | 1 | 2015 | 710 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2015 | 2470 | 0.020 |
Why?
|
Death | 1 | 2015 | 686 | 0.020 |
Why?
|
Multiprotein Complexes | 1 | 2017 | 1108 | 0.020 |
Why?
|
Catheters | 1 | 2014 | 426 | 0.020 |
Why?
|
Proteinuria | 1 | 2013 | 606 | 0.020 |
Why?
|
Central Nervous System | 1 | 2017 | 1342 | 0.020 |
Why?
|
Metabolomics | 1 | 2019 | 1668 | 0.020 |
Why?
|
Radiotherapy Dosage | 2 | 2008 | 2864 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2008 | 5336 | 0.020 |
Why?
|
Signal Transduction | 3 | 2017 | 23589 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2015 | 2108 | 0.020 |
Why?
|
Mice, Nude | 1 | 2015 | 3614 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 3595 | 0.020 |
Why?
|
Risk Factors | 1 | 2016 | 74831 | 0.020 |
Why?
|
Blotting, Western | 1 | 2015 | 5019 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2000 | 3683 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2000 | 4423 | 0.020 |
Why?
|
Software | 1 | 2001 | 4459 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2014 | 1856 | 0.020 |
Why?
|
Infant Behavior | 1 | 2008 | 156 | 0.020 |
Why?
|
Infant Care | 1 | 2008 | 181 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2016 | 2878 | 0.020 |
Why?
|
Fatigue | 1 | 2013 | 1550 | 0.020 |
Why?
|
Phosphorylation | 1 | 2017 | 8279 | 0.020 |
Why?
|
Disease Management | 1 | 2016 | 2534 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2022 | 9522 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2019 | 7599 | 0.020 |
Why?
|
Equipment Design | 1 | 2014 | 3485 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2018 | 9548 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2941 | 0.020 |
Why?
|
DNA Repair | 1 | 2015 | 2051 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3432 | 0.020 |
Why?
|
Cisplatin | 1 | 2011 | 1657 | 0.010 |
Why?
|
Cell Movement | 1 | 2017 | 5192 | 0.010 |
Why?
|
HIV Infections | 1 | 2011 | 17531 | 0.010 |
Why?
|
Intraoperative Care | 1 | 2007 | 760 | 0.010 |
Why?
|
Kidney | 1 | 1999 | 7066 | 0.010 |
Why?
|
Facial Paralysis | 1 | 2007 | 346 | 0.010 |
Why?
|
Cohort Studies | 1 | 2006 | 41631 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2011 | 6203 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2000 | 9245 | 0.010 |
Why?
|
Tandem Mass Spectrometry | 1 | 2009 | 1193 | 0.010 |
Why?
|
Automation | 1 | 2004 | 585 | 0.010 |
Why?
|
Social Support | 1 | 2011 | 2193 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26284 | 0.010 |
Why?
|
Hemorrhage | 1 | 2013 | 3461 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2017 | 10428 | 0.010 |
Why?
|
Apoptosis | 1 | 2017 | 9511 | 0.010 |
Why?
|
Brain Mapping | 1 | 2016 | 6598 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2015 | 5781 | 0.010 |
Why?
|
Idoxuridine | 1 | 2000 | 111 | 0.010 |
Why?
|
Aldehyde Oxidoreductases | 1 | 2000 | 88 | 0.010 |
Why?
|
Incidence | 1 | 2018 | 21478 | 0.010 |
Why?
|
Ferrets | 1 | 2000 | 182 | 0.010 |
Why?
|
DNA Methylation | 1 | 2014 | 4425 | 0.010 |
Why?
|
Stem Cell Transplantation | 1 | 2008 | 1601 | 0.010 |
Why?
|
Middle Aged | 3 | 2024 | 222903 | 0.010 |
Why?
|
Hematologic Tests | 1 | 2000 | 239 | 0.010 |
Why?
|
Patient Participation | 1 | 2008 | 1455 | 0.010 |
Why?
|
Staurosporine | 1 | 2000 | 240 | 0.010 |
Why?
|
Urine | 1 | 2000 | 360 | 0.010 |
Why?
|
Radiotherapy | 1 | 2005 | 1494 | 0.010 |
Why?
|
Aged | 3 | 2024 | 171050 | 0.010 |
Why?
|
Neurons | 1 | 2017 | 9521 | 0.010 |
Why?
|
Prodrugs | 1 | 2000 | 273 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 2007 | 2673 | 0.010 |
Why?
|
Neurosurgical Procedures | 1 | 2007 | 2081 | 0.010 |
Why?
|
Stomach | 1 | 2000 | 700 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 1999 | 20667 | 0.010 |
Why?
|
Sex Factors | 1 | 2009 | 10605 | 0.010 |
Why?
|
Hypertension | 1 | 2013 | 8626 | 0.010 |
Why?
|
Bone Marrow | 1 | 2000 | 2918 | 0.010 |
Why?
|
Schizophrenia | 1 | 2008 | 6973 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2000 | 3451 | 0.000 |
Why?
|
DNA | 1 | 2000 | 7200 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 2012 | 59459 | 0.000 |
Why?
|
B-Lymphocytes | 1 | 2000 | 4779 | 0.000 |
Why?
|
Liver | 1 | 2000 | 7559 | 0.000 |
Why?
|
T-Lymphocytes | 1 | 2000 | 10262 | 0.000 |
Why?
|